For example, its taken daily instead of weekly, and you might lose less weight with it than with other injectable GLP-1 medications
Orandi At 5 years of follow-up, significantly fewer GLP-1 drug users (7.5%) than nonusers (12.2%) experienced death-censored graft loss, for a 49% lower risk for graft loss with GLP-1 drug use when adjusted for insulin use (adjusted subhazard ratio [aSHR] = 0.51
Murakami T, Nishiyama T, Shirotani T, Shinohara Y, Kan M, Ishii K, Kanai F, Nakazuru S, Ebina Y
Montero, G
STAT News cited a recently published British Medical Journal review of 37 studies, tallying an aggregate of more than 9,300 participants, in which approximately 50% of the people who started on the drugs stop taking them within one year
Combination of PDE5 inhibitors with adjunctive therapies